|
|
 |
|
Viewing report
|
|
|
|
OTC Obesity in Austria
Euromonitor International, April 2010, Pages: 31
GlaxoSmithKline’s Alli was introduced in April 2009, as in all other European countries. The sales for 2009 were estimated at EUR100,000. This corresponds to a minimum of 520 consumers, assuming an average price of EUR0.80 per Alli pill once a day, used for eight months in 2009. While slimming products were not taken seriously in 2009, this product is likely to be considered as effective support for weight loss.
The OTC Obesity Products in Austria report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2005-2009, allowing you to identify the sectors driving growth. Forecasts to 2014 illustrate how the market is set to change.
Product coverage:
Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.
Why buy this report?
- Get a detailed picture of the Consumer Health industry;
- Pinpoint growth sectors and identify factors driving change;
- Understand the competitive environment, the market’s major players and leading brands;
- Use five-year forecasts to assess how the market is predicted to develop.
.
Customers who bought this item also bought
Slimming Products in Austria
Wound Treatments in Austria
Cough, Cold and Allergy (hay Fever) Remedies in Austria
Vitamins and Dietary Supplements in Austria
Analgesics in Germany
Wound Care in Austria
OTC Obesity in Germany
Weight Management in Austria
Digestive Remedies in Germany
Digestive Remedies in Austria
|
|
|
|
